Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study

References

• HughesEBassiSGilbodySBlandMMartinFPrevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysisLancet Psychiatry201631404826620388
   PubMed Web of Science ®Google Scholar
• CoillyARocheBDuclos-ValleeJCSamuelDNews and challenges in the treatment of hepatitis C in liver transplantationLiver Int201636suppl 1344226725895
   PubMed Web of Science ®Google Scholar
• GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology and genotype distribution of the hepatitis C virus infectionJ Hepatol2014611 supplS45S5725086286
   PubMed Web of Science ®Google Scholar
• AlkhouriNZeinNNProtease inhibitors: silver bullets for chronic hepatitis C infection?Cleve Clin J Med201279321322222383557
   PubMed Web of Science ®Google Scholar
• MessinaJPHumphreysIFlaxmanAGlobal distribution and prevalence of hepatitis C virus genotypesHepatology2015611778725069599
   PubMed Web of Science ®Google Scholar
• KretzerIFdo LivramentoAda CunhaJHepatitis C worldwide and in Brazil: silent epidemic – data on disease including incidence, transmission, prevention, and treatmentScientificWorldJournal2014201482784925013871
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of HealthBoletim Epidemiológico – Hepatites ViraisBrazilSecretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Brasilia, Ministry of Health2015
   Google Scholar
• FerreiraPRBrandao-MelloCEEstesCDisease burden of chronic hepatitis C in BrazilBraz J Infect Dis201519436336826051505
   PubMed Web of Science ®Google Scholar
• WebsterDPKlenermanPDusheikoGMHepatitis CLancet201538599731124113525687730
   PubMed Web of Science ®Google Scholar
• KauAVermehrenJSarrazinCTreatment predictors of a sustained virologic response in hepatitis B and CJ Hepatol200849463465118715665
   PubMed Web of Science ®Google Scholar
• ThorntonKDemingPManchRAIs response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatmentHepatol Int201610462463127098355
   PubMed Web of Science ®Google Scholar
• FedericoAMasaroneMRomanoMDallioMRosatoVPersicoMRapid virological response represents the highest prediction factor of response to antiviral treatment in HCV-related chronic hepatitis: a multicenter retrospective studyHepat Mon2015156e1864026286149
   PubMed Web of Science ®Google Scholar
• FeeneyERChungRTAntiviral treatment of hepatitis CBMJ2014348g330825002352
   PubMed Web of Science ®Google Scholar
• ShahidIWHALHafeezMHHassanSHepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategiesCrit Rev Microbiol201642453554725373616
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of HealthInibidores de Protease (Boceprevir e Telaprevir) para o tratamento da Hepatite Crônica CBrazilSecretariat of Science, Technology and Strategic Inputs. Department of Science and Technology, Brasília, Ministry of Health2012
   Google Scholar
• Brazilian Ministry of HealthSimeprevir, sofosbuvir e daclatasvir no tratamento da hepatite crônica tipo C e coinfecçõesBrazilSecretariat of Science, Technology and Strategic Inputs. Department of Science and Technology, Brasília, Ministry of Health2015
   Google Scholar
• BedossaPIntraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C: the French METAVIR Cooperative Study GroupHepatology199420115208020885
   PubMed Web of Science ®Google Scholar
• FabriziFMartinPCacoubPMessaPDonatoFMTreatment of hepatitis C-related kidney diseaseExpert Opin Pharmacother201516121815182726161511
   PubMed Web of Science ®Google Scholar
• RubinRARussoMWBrownKATwice-daily telaprevir for posttransplant genotype 1 hepatitis C virus: a prospective safety, efficacy, and pharmacokinetics studyExp Clin Transplant Epub20161118
   PubMed Web of Science ®Google Scholar
• de BruijnWIbanezCFriskPIntroduction and utilization of high priced HCV medicines across Europe; implications for the futureFront Pharmacol2016719727516740
   PubMed Web of Science ®Google Scholar
• PoordadFReddyKRMartinPRapid virologic response: a new milestone in the management of chronic hepatitis CClin Infect Dis2008461788418171217
   PubMed Web of Science ®Google Scholar
• CavalcanteLNLyraACPredictive factors associated with hepatitis C antiviral therapy responseWorld J Hepatol20157121617163126140082
   PubMedGoogle Scholar
• YuMLDaiCYHuangJFRapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trialHepatology20084761884189318508296
   PubMed Web of Science ®Google Scholar
• JensenDMMorganTRMarcellinPEarly identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapyHepatology200643595496016628671
   PubMed Web of Science ®Google Scholar
• BaillyFVirlogeuxVDufourCEarly virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – the ANRS CO20-CUPIC studyClin Res Hepatol Gastroenterol201539444345025636238
   PubMed Web of Science ®Google Scholar
• BelperioPSHwangEWThomasICMoleLACheungRCBackusLIEarly virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis CClin Gastroenterol Hepatol20131181021102723524130
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• BlackNWhy we need observational studies to evaluate the effectiveness of health careBMJ19963127040121512188634569
   PubMed Web of Science ®Google Scholar
• AlmeidaPRFonsecaCBKochVWSouzaAMFeltrinAATovoCVTriple therapy in chronic hepatitis C: initial series in a public health program in the South of BrazilArq Gastroenterol2015521141726017076
   PubMedGoogle Scholar
• PearlmanBLEhlebenCHepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitorHepatology2014591717723873583
   PubMed Web of Science ®Google Scholar
• TeixeiraRNascimento YdeACrespoDSafety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactionsBraz J Infect Dis201317219420423490868
   PubMed Web of Science ®Google Scholar